DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20162897

Secukinumab - a stupendous option in psoriasis management

Damal Kandadai Sriram, Melvin George, Krishnamoorthy Snehalatha, Govindaraj Gowri

Abstract


Psoriasis is a chronic inflammatory skin disease with increased epidermal proliferation related to dysregulation of the immune system. In spite of several therapeutic strategies available for the treatment of this condition, the disease causes untold suffering particularly in the severe variant of the disease. Secukinumab is a human IgG1 monoclonal antibody that binds to the cytokine interleukin-17A (IL-17A) inhibiting the pro-inflammatory effects that are involved in the development of plaque psoriasis. Secukinumab 300mg is to be given via subcutaneous injection at weeks 0, 1, 2, 3 and 4 and once monthly thereafter. The efficacy of secukinumab has been evaluated in three phase 3 clinical trials. The drug showed an overwhelming improvement in the primary end points as assessed by PASI 75 and modified IGA scores.  The only major concern with secukinumab is the increased risk of nasopharyngitis and mucocutaneous candidiasis due to the interference with host defence mechanisms by targeting IL-17.  Secukinumab has also shown favorable response in the treatment of psoriatic arthritis, ankylosing spondylitis from clinical trials. The drug has been approved by the US FDA in January 2015 for the treatment of moderate to severe psoriasis in patients who require systemic therapy. Nevertheless long term safety data are still awaited. While the results of these trials have been extremely gratifying, it remains to be seen if the stupendous performance displayed in clinical trials could be translated in real world practice.


Keywords


Secukinumab, Psoriasis, Novel drug, Interleukin-17A, PASI 75

Full Text:

PDF

References


Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CEM, Papp K, et al. Secukinumab in plaque psoriasis results of two phase 3 trials. N Engl J Med. 2014;371(4):326-38.

Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study [Internet]. 1111. Available from: ClinicalTrials.gov number: NCT00941031

Chen X, Yang M, Cheng Y, Liu GJ, Zhang M. Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis. Cochrane Database Syst Rev. 2013;10:CD009481.

Thaçi D, Blauvelt A, Reich K, Tsai T-F, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400-9.

Thaçi D, Humeniuk J, Frambach Y, Bissonnette R, Goodman JJ, Shevade S, et al. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). Br J Dermatol. 2015;173(3):777-87.

Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484-93.

McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2015;19;386(9999):1137-46.

Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet Lond Engl. 2013;382(9906):1705-13.

McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2015;386(9999):1137-46.

Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011;332(6025):65-8.

Roman M, Madkan VK, Chiu MW. Profile of secukinumab in the treatment of psoriasis: current perspectives. Ther Clin Risk Manag. 2015;11:1767-77.

Klibanov OM, Phan D, Ferguson K. Drug updates and approvals: 2015 in review. Nurse Pract. 2015;40(12):34-43-4.

Tausend W, Downing C, Tyring S. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab. J Cutan Med Surg. 2014;18(3):156-69.

van den Berg WB, McInnes IB. Th17 cells and IL-17 a--focus on immunopathogenesis and immunotherapeutics. Semin Arthritis Rheum. 2013;43(2):158-70.

Lee A, Gregory V, Gu Q, Becker DL, Barbeau M. Cost-effectiveness of Secukinumab compared to current treatments for the treatment of moderate to severe plaque Psoriasis in Canada.

Highlights of Prescribing Information [Revised January 1, 2015].